Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Coronavirus COVID-19 Vaccines Sales & Earnings

J&J Forecasts Strong Pharma Growth In 2021, But No COVID-19 Vaccine Update

Executive Summary

Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.

You may also be interested in...



Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio catch-up on the latest key developments in the worldwide biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.

J&J Finishes Tough Year With Optimism For 2021

J&J expects its medical device sales to begin growing rapidly by the middle of 2021 as the pandemic subsides.

Moderna Takes The Lead With Plan To Tackle New COVID-19 Variants

Moderna has unveiled plans to develop a new booster vaccine, tweaked to meet the threat posed by the South African strain.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Coronavirus COVID-19 Vaccines Sales & Earnings
Latest Headlines

The Game Looks Up For Galecto

ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow

Ionis Closer To First Wholly-Owned Drug Launch With Olezarsen Phase III Success

Asia Deal Watch: Inventiva Finds Japan/Korea Partner For Phase III NASH Candidate In Hepalys

See All
UsernamePublicRestriction

Register

SC143699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By